Trial Profile

A phase II a trial assessing brilaroxazine in attention deficit hyperactivity disorder (ADHD)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 09 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brilaroxazine (Primary)
Indications Attention-deficit hyperactivity disorder
Focus Therapeutic Use

Most Recent Events

04 Jan 2024 According to a Reviva Pharmaceuticals media release, the company is planning to initiate this study in 2024.
30 Mar 2023 According to a Reviva Pharmaceuticals media release, the company is planning to initiate this study in second half 2023, subject to the receipt of additional financing.
04 Jan 2023 According to a Reviva Pharmaceuticals media release, the company is planning to initiate this study in 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com